Evidence map›Paper›PMID 31932015›Full record

ArticleAtencion primaria

Short-term mortality in end-stage heart failure patients.

Jose Maria Verdú-Rotellar, Esther Calero, Rosa Abellana, José Verdú-Soriano, Ernest Vinyoles, José Luis Del Val-García, Mar Domingo, Miguel-Angel Muñoz

Abstract readMulticenter Study
In one paragraph

Article in Atencion primaria. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jose Maria Verdú-RotellarGerencia Atención Primaria de Barcelona, Institut Català de la Salut, Barcelona, Spain; Primary Health Care University Research Institute Jordi Gol (IDIAPJGol), Barcelona, Spain; School of Medicine, Universitat Autonoma de Barcelona, Bellaterra, Spain.
Esther CaleroPrimary Health Care University Research Institute Jordi Gol (IDIAPJGol), Barcelona, Spain; Community Nursing, Preventive Medicine, Public Health and History of Science Department, Faculty of Health Sciences, University of Alicante, Spain; Hospital Universitari de Bellvitge, Institut Català de la Salut, L'Hospitalet de Llobregat, Barcelona, Spain.
Rosa AbellanaPrimary Health Care University Research Institute Jordi Gol (IDIAPJGol), Barcelona, Spain; School of Medicine, Universitat de Barcelona, Barcelona, Spain.
José Verdú-SorianoCommunity Nursing, Preventive Medicine, Public Health and History of Science Department, Faculty of Health Sciences, University of Alicante, Spain.
Ernest VinyolesGerencia Atención Primaria de Barcelona, Institut Català de la Salut, Barcelona, Spain; Primary Health Care University Research Institute Jordi Gol (IDIAPJGol), Barcelona, Spain; School of Medicine, Universitat de Barcelona, Barcelona, Spain.
José Luis Del Val-GarcíaGerencia Atención Primaria de Barcelona, Institut Català de la Salut, Barcelona, Spain; Primary Health Care University Research Institute Jordi Gol (IDIAPJGol), Barcelona, Spain.
Mar DomingoHeart Failure Unit, Hospital Universitari Germans Trias i Pujol, Institut Català de la Salut, Badalona, Spain.
Miguel-Angel MuñozGerencia Atención Primaria de Barcelona, Institut Català de la Salut, Barcelona, Spain; Primary Health Care University Research Institute Jordi Gol (IDIAPJGol), Barcelona, Spain; School of Medicine, Universitat Autonoma de Barcelona, Bellaterra, Spain. Electronic address: mamunoz.bcn.ics@gencat.cat.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThis study is aimed at analyzing the impact of the main factors contributing to short and long-term mortality in patients at final stages of heart failure (HF).

settingPatients attended at any of the 279 primary health care centers belonging to the Institut Català de la Salut, in Catalonia (Spain).

participantsPatients with Advanced HF.

designMulticenter cohort study including 1148 HF patients followed for one-year after reaching New York Heart Association (NYHA) IV. MAIN MEASUREMENTS: The primary outcome was all-cause mortality. Multivariate logistic regression models were performed to assess the outcomes at 1, 3, 6, and 12 months.

resultsMean age of patients was 82 (SD 9) years and women represented 61.7%. A total of 135 (11.8%) and 397 (34.6%) patients died three months and one year after inclusion, respectively. Male gender, age, and decreased body mass index were associated with higher mortality at three, six and twelve months. In addition, low systolic blood pressure levels, severe reduction in glomerular filtration, malignancy, and higher doses of loop diuretics were related to higher mortality from 6 to 12 months. The most important risk factor over the whole period was presenting a body mass index lower than 20kg/m

conclusionsWe may conclude that male, age, and decreased body mass index determined higher short-term mortality in NYHA IV. In addition, low systolic blood pressure, reduced glomerular filtration, malignancy, and higher doses of loop diuretics contribute to increasing the risk of mortality at medium and long-term. Such variables are easily measurable and can help to decide the best way to face the most advances stages of the disease.

Indexed as

Angiotensin Receptor AntagonistsHeart FailureAgedAged, 80 and overAngiotensin-Converting Enzyme InhibitorsCohort StudiesFemaleHumansMaleRisk FactorsAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsEnd of lifeEpidemiologíaEpidemiologyFactores pronósticosFin de vidaHeart failureInsuficiencia cardíacaPrognostic factors

Identifiers

PMID31932015
PMCPMC7393541

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.